Analyst Price Targets — ERAS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 7:53 pm | — | Jefferies | $24.00 | $19.50 | StreetInsider | Erasca Inc (ERAS) PT Raised to $24 at Jefferies, 'underappreciated'Member Login |
| July 14, 2026 10:59 am | — | HSBC | $20.00 | $17.90 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Erasca Inc (ERAS) |
| June 4, 2026 9:12 am | — | Wolfe Research | $16.00 | $13.18 | StreetInsider | BofA Securities Upgrades Erasca Inc (ERAS) to Neutral, 'we see the downside case as now less compelling' |
| May 12, 2026 11:15 am | — | Mizuho Securities | $26.00 | $10.44 | TheFly | Erasca price target lowered to $26 from $28 at Mizuho |
| April 27, 2026 10:40 am | — | Stifel Nicolaus | $30.00 | $21.50 | TheFly | Erasca price target raised to $30 from $20 at Stifel |
| March 10, 2026 6:36 pm | Laura Prendergast | Stifel Nicolaus | $20.00 | $15.58 | StreetInsider | Erasca Inc (ERAS) PT Raised to $20 at Stifel |
| January 27, 2026 12:16 pm | — | Guggenheim | $12.00 | $9.61 | TheFly | Erasca price target raised to $12 from $5 at Guggenheim |
| January 26, 2026 11:47 am | Sean Laaman | Morgan Stanley | $10.00 | $9.96 | TheFly | Erasca price target raised to $10 from $4 at Morgan Stanley |
| January 16, 2026 11:55 am | — | Piper Sandler | $11.00 | $9.56 | TheFly | Erasca price target raised to $11 from $5 at Piper Sandler |
| January 12, 2026 5:12 pm | Laura Prendergast | Stifel Nicolaus | $10.00 | $6.23 | StreetInsider | Erasca Inc (ERAS) PT Raised to $10 at Stifel |
Latest News for ERAS
NEW YORK, July 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. So what: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment…
/PRNewswire/ -- - Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc
Erasca, Inc. offers exposure to the RAS/MAPK oncology space at a fraction of Revolution Medicines' valuation, with a $6.7bn market cap versus RVMD's $38.5bn. ERAS-0015's Phase 1 data show promising efficacy and safety, with higher response rates and lower severe adverse events compared to Revolution's daraxonrasib. Patent infringement allegations from Revolution and a patient death initially pressured ERAS, but…
New York, New York--(Newsfile Corp. - July 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) on behalf of investors that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Erasca and have…
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) of a class action securities lawsuit.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ERAS.
U.S. House Trading
No House trades found for ERAS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.